



Tumour Angiogenesis

Guest Editor:

Dr. Ruowen Ge

Department of Biological
Sciences, National University of
Singapore, Singapore 117558,
Singapore

Deadline for manuscript
submissions:

closed (30 April 2013)

Message from the Guest Editor

Dear Colleagues,

Tumor angiogenesis is critical for both tumor progression and metastasis. Hence targeting tumor angiogenesis as a therapeutic anticancer approach has been actively pursued for many years. Despite the initial success in animal tumor models and some degree of effectiveness in prolonging the survival of human cancer patients, limitations of efficacy plus inherent as well as acquired resistance in human cancers still plague this therapeutic approach. Hence, further understanding of the molecular and cellular mechanisms of tumor angiogenesis are essential for the advancement of effective antiangiogenic therapy. This special issue will focus on new advancement in the biology and drug targeting of tumor angiogenesis.

We are looking forward to your contributions.

Dr. Ruowen Ge
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)